Source:http://linkedlifedata.com/resource/pubmed/id/20644086
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
24
|
| pubmed:dateCreated |
2010-8-19
|
| pubmed:abstractText |
PURPOSE We previously reported our results with a single-agent arsenic trioxide (ATO) -based regimen in newly diagnosed cases of acute promyelocytic leukemia (APL). The concern remained about the long-term outcome of this well-tolerated regimen. We report our long-term follow-up data on the same cohort. PATIENTS AND METHODS From January 1998 to December 2004, 72 patients with PML/RARalpha+ APL were enrolled. All patients were treated with a single-agent ATO regimen. Results Overall 62 (86.1%) achieved a hematologic remission (complete remission). After the initial report, an additional seven patients have relapsed for a total of 13 relapses. There were no additional toxicities to report on follow-up. At a median follow-up 60 months, the 5-year Kaplan-Meier estimate (+/- SE) of event-free survival, disease-free survival, and overall survival (OS) was 69% +/- 5.5%, 80% +/- 5.2%, and 74.2% +/- 5.2%, respectively. The OS in the good risk group as defined by us remains 100% over this period. CONCLUSION Single-agent ATO as used in this study in the management of newly diagnosed cases of APL is safe and is associated with durable responses. Results in the low-risk group are comparable to that reported with conventional therapy while additional interventions would probably be required in high-risk cases.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1527-7755
|
| pubmed:author |
pubmed-author:AbrahamAbyA,
pubmed-author:BalasubramanianPoonkuzhaliP,
pubmed-author:ChandyMammenM,
pubmed-author:ChendamaraiEzhilarasiE,
pubmed-author:DesireSalamunS,
pubmed-author:GeorgeBijuB,
pubmed-author:LakshmiKavitha MKM,
pubmed-author:MathewsVikramV,
pubmed-author:ShajiRamachandran VelayudhanRV,
pubmed-author:SrivastavaAlokA,
pubmed-author:ThirugnanamRajashekarR,
pubmed-author:ViswabandyaAuroA
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
20
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3866-71
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:20644086-Adult,
pubmed-meshheading:20644086-Aged,
pubmed-meshheading:20644086-Antineoplastic Agents,
pubmed-meshheading:20644086-Arsenicals,
pubmed-meshheading:20644086-Disease-Free Survival,
pubmed-meshheading:20644086-Female,
pubmed-meshheading:20644086-Follow-Up Studies,
pubmed-meshheading:20644086-Hair,
pubmed-meshheading:20644086-Humans,
pubmed-meshheading:20644086-Infusions, Intravenous,
pubmed-meshheading:20644086-Kaplan-Meier Estimate,
pubmed-meshheading:20644086-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:20644086-Male,
pubmed-meshheading:20644086-Middle Aged,
pubmed-meshheading:20644086-Nails,
pubmed-meshheading:20644086-Oxides,
pubmed-meshheading:20644086-Recurrence,
pubmed-meshheading:20644086-Remission Induction,
pubmed-meshheading:20644086-Time Factors,
pubmed-meshheading:20644086-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
|
| pubmed:affiliation |
Department of Haematology, Christian Medical College and Hospital, Vellore 632004, India; vikram@cmcvellore.ac.in.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|